A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Engineered Extracellular Vesicles for Cancer Therapy
Tekijät: Zhang Xu, Zhang Hongbo, Gu Jianmei, Zhang Jiayin, Shi Hui, Qian Hui, Wang Dongqing, Xu Wenrong, Pan Jianming, Santos Hélder A
Kustantaja: WILEY-V C H VERLAG GMBH
Julkaisuvuosi: 2021
Journal: Advanced Materials
Tietokannassa oleva lehden nimi: ADVANCED MATERIALS
Lehden akronyymi: ADV MATER
Artikkelin numero: ARTN 2005709
Vuosikerta: 33
Numero: 14
Sivujen määrä: 25
ISSN: 0935-9648
eISSN: 1521-4095
DOI: https://doi.org/10.1002/adma.202005709
Rinnakkaistallenteen osoite: https://helda.helsinki.fi/bitstream/10138/333009/1/adma202005709_Corrected_proofs1.pdf
Tiivistelmä
Extracellular vesicles (EVs) have emerged as a novel cell-free strategy for the treatment of many diseases including cancer. As a result of their natural properties to mediate cell-to-cell communication and their high physiochemical stability and biocompatibility, EVs are considered as excellent delivery vehicles for a variety of therapeutic agents such as nucleic acids and proteins, drugs, and nanomaterials. Increasing studies have shown that EVs can be modified, engineered, or designed to improve their efficiency, specificity, and safety for cancer therapy. Herein, a comprehensive overview of the recent advances in the strategies and methodologies of engineering EVs for scalable production and improved cargo-loading and tumor-targeting is provided. Additionally, the potential applications of engineered EVs in cancer therapy are discussed by presenting prominent examples, and the opportunities and challenges for translating engineered EVs into clinical practice are evaluated.
Extracellular vesicles (EVs) have emerged as a novel cell-free strategy for the treatment of many diseases including cancer. As a result of their natural properties to mediate cell-to-cell communication and their high physiochemical stability and biocompatibility, EVs are considered as excellent delivery vehicles for a variety of therapeutic agents such as nucleic acids and proteins, drugs, and nanomaterials. Increasing studies have shown that EVs can be modified, engineered, or designed to improve their efficiency, specificity, and safety for cancer therapy. Herein, a comprehensive overview of the recent advances in the strategies and methodologies of engineering EVs for scalable production and improved cargo-loading and tumor-targeting is provided. Additionally, the potential applications of engineered EVs in cancer therapy are discussed by presenting prominent examples, and the opportunities and challenges for translating engineered EVs into clinical practice are evaluated.
Turun yliopiston Tutkimustietojärjestelmän portaali